Literature DB >> 17349524

Pathologic findings at radical prostatectomy: risk factors for failure and death.

Gregory P Swanson1, Mark Riggs, Michael Hermans.   

Abstract

BACKGROUND: Failure after radical prostatectomy can occur even out to 25 years after surgery. Therefore, it is important that studies have sufficient follow-up to determine more accurately the risk of failure. We evaluated a large cohort of patients for pathologic findings and risk of failure with a median follow-up of 9.5 years.
MATERIAL AND METHODS: Between 1985 and 1995, 719 patients underwent radical prostatectomy for lymph node negative prostate cancer. The prostate was inked and evaluated for: (1) positive bladder neck or urethral margin, (2) positive seminal vesicle, (3) into capsule, (4) through capsule, and (5) positive margin. These were considered positive pathologic findings.
RESULTS: Overall, 264 (37%) of the patients had biochemical recurrence. For those patients with failure, median time to biochemical recurrence was 2.4 years. Five and 10-year biochemical failure rates were 28% and 38%, respectively. Pathologic stage of disease significantly (<0.0001) predicted for subsequent failure. If there were no positive pathology findings, the recurrence rate was 25%, compared to 63% for any of the 3 findings. Overall, 212 (29%) of the patients have died. Five and 10-year survival were 91% and 75%, respectively. A total of 45 patients (6%) died of prostate cancer. For patients with negative pathology findings, 3% died as a direct consequence of prostate cancer, compared to 13% if the pathology was positive. Of the patients with positive seminal vesicle, 28% died of cancer.
CONCLUSION: Patients with any of the following factors have a risk of failure exceeding 40% and are candidates for studies of adjuvant therapy: seminal vesicle involvement, extension through the capsule, or margin involvement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349524     DOI: 10.1016/j.urolonc.2006.06.003

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  39 in total

1.  Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naïve patients.

Authors:  Ji Eun Heo; Jee Soo Park; Jong Soo Lee; Jongchan Kim; Won Sik Jang; Nam Hoon Cho; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Won Sik Ham
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-14       Impact factor: 4.553

2.  What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.

Authors:  Anna E Teeter; Lionel L Bañez; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

3.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

4.  Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling.

Authors:  Nitin Ohri; Xinglei Shen; Robert B Den; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

5.  Impact of the extent of extraprostatic extension defined by Epstein's method in patients with negative surgical margins and negative lymph node invasion.

Authors:  T Maubon; N Branger; C Bastide; G Lonjon; K-A Harvey-Bryan; P Validire; S Giusiano; D Rossi; X Cathelineau; F Rozet
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-12       Impact factor: 5.554

6.  [Radiotherapy of prostate cancer].

Authors:  S Krause; K Herfarth
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

7.  Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes.

Authors:  Mark V Mishra; Eli D Scher; Jocelyn Andrel; Andrew C Margules; Sarah E Hegarty; Edouard J Trabulsi; Terry Hyslop; Robert B Den; Costas D Lallas; Leonard G Gomella; Adam P Dicker; Timothy N Showalter
Journal:  Am J Clin Oncol       Date:  2015-02       Impact factor: 2.339

8.  Impact of Gleason score on biochemical recurrence in patients with pT3aN0/Nx prostate cancer with positive surgical margins: a multicenter study from the Prostate Cancer Research Committee.

Authors:  Wan Song; Dong Hyeon Lee; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han Yong Choi; Jong Wook Kim; SangChul Lee; Seok-Soo Byun; Chang Wook Jeong; Cheol Kwak; Jin Seon Cho; Hanjong Ahn; Seong Soo Jeon
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-19       Impact factor: 4.553

9.  Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.

Authors:  T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi
Journal:  Ann Oncol       Date:  2011-06-09       Impact factor: 32.976

10.  Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.

Authors:  Mariam Imnadze; Daniel D Sjoberg; Andrew J Vickers
Journal:  Eur Urol       Date:  2015-04-23       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.